Immunophotonics

Immunophotonics

Pharmaceuticals, 4340 Duncan Ave, St. Louis, Missouri, 63110, United States, 11-50 Employees

immunophotonics.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 31********

Who is IMMUNOPHOTONICS

Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently devel...

Read More

map
  • 4340 Duncan Ave, St. Louis, Missouri, 63110, United States Headquarters: 4340 Duncan Ave, St. Louis, Missouri, 63110, United States
  • 2012 Date Founded: 2012
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $5 Million to $10 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 8011

checked-icon Does something look wrong? Fix it. | View contact records from IMMUNOPHOTONICS

Immunophotonics Org Chart and Mapping

Employees

Alexander Hurst

General Counsel and VP of Operations

Jennifer Li

Non-Clinical R&D Intern

Abby Delawder

Principal Scientist, Cmc

Theresa Visarius

Vice President Business Development (Immunophotonics, Inc.) Managing Director (Ips Biopharma Ag)

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Immunophotonics

Answer: Immunophotonics's headquarters are located at 4340 Duncan Ave, St. Louis, Missouri, 63110, United States

Answer: Immunophotonics's phone number is 31********

Answer: Immunophotonics's official website is https://immunophotonics.com

Answer: Immunophotonics's revenue is $5 Million to $10 Million

Answer: Immunophotonics's SIC: 8011

Answer: Immunophotonics has 11-50 employees

Answer: Immunophotonics is in Pharmaceuticals

Answer: Immunophotonics contact info: Phone number: 31******** Website: https://immunophotonics.com

Answer: Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently developing its first asset, the immune-modulating proprietary carbohydrate polymer IP-001 for the treatment of solid tumor cancers. IP-001 has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their surveillance of tumor tissue and can generate long-term protective immunity.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access